Ironwood Pharmaceuticals reported adjusted earnings of 31 cents per share for the second quarter of 2026, beating the Zacks Consensus Estimate of 26 cents. Total revenues were $113 million, missing the estimate of $120 million but surging 32.6% year over year. The company raised its full-year 2026 revenue guidance to a range of $460 to $485 million, up from the prior $450 to $475 million, driven by higher demand for Linzess. U.S. sales of Linzess, recorded by partner AbbVie, are now expected to be between $1.15 billion and $1.20 billion, compared with the earlier projection of $1.13 billion to $1.18 billion. Ironwood also lifted its adjusted EBITDA outlook to more than $310 million from more than $300 million.
Ironwood Pharmaceuticals IncBeats Q2 earnings estimates and raises full-year revenue and EBITDA guidance.
AbbVie IncLinzess U.S. sales guidance raised, indicating strong demand for the product.
AstraZeneca PLC
Liquidia Technologies Inc